Methylphenidate

6% of U.S. adults have ADHD; 71.5% of those on stimulant meds face difficulties due to drug shortages, impacting treatment and increasing risks.

Athletic trainer Kenya Moore noticed a player's disorientation after switching ADHD meds, leading to heat stroke. Experts warn that medications for ADHD, anxiety, and depression elevate heat stroke risk in athletes, calling for more research. Heat illness diagnoses and deaths have risen with global temperatures, with stimulants potentially increasing risk by constricting blood vessels and inhibiting sweating. Awareness and precautions are crucial, especially as mental health medication use rises.

Dr. Thomas Hutson discusses kidney cancer treatment decisions, including the continuation or cessation of Keytruda and Inlyta after two years of complete response, and the use of Lenvima and Afinitor for non-clear cell chromophobe renal cell carcinoma. He also addresses managing severe fatigue and chronic kidney disease, protein intake for renal cell carcinoma patients, and the challenges of clinical trial accessibility for rural patients.

High-dose prescription amphetamine users face over five-fold increased risk of psychosis or mania, with 30 mg+ dextroamphetamine (40 mg Adderall) posing the highest risk, according to McLean Hospital research. The study, published in the American Journal of Psychiatry, highlights the need for dose consideration in prescribing stimulants, with 81% of psychosis or mania cases in high-dose users potentially preventable. No significant risk increase was observed with methylphenidate (Ritalin) use.

DEA allows increased production of Vyvanse to address ADHD and BED treatment shortages, with 25% for domestic and 75% for foreign demand. Despite FDA approval for generic Vyvanse production, shortages persist due to active ingredient issues. DEA's quota-setting process faces criticism for causing shortages, prompting consideration of more transparent methods. Vyvanse remains the most popular stimulant among ADDitude survey respondents.

High doses of ADHD meds like Adderall can increase psychosis risk by over fivefold, with 30mg+ dextroamphetamine (40mg Adderall) posing the highest risk, according to a study in the American Journal of Psychiatry. Dr. Lauren Moran emphasizes dose as a critical factor in psychosis risk and suggests considering alternative ADHD treatments like methylphenidate (Ritalin), which showed no increased risk.